$XTALPI(02228.HK) On April 20th, the FDA released a one-year progress report on the implementation of the "Roadmap for Reducing Preclinical Animal Testing (2025)": After a year of planning and advancement, the FDA has fulfilled all its first-year commitments as scheduled. The "animal-free drug research" pathway, centered on New Approach Methodologies (NAMs), is gradually becoming an industry consensus. In a statement, FDA Commissioner Dr. Marty Makary stated directly that phasing out unnecessary animal testing is essentially about "reconstructing the drug safety evaluation system with scientific methods that better align with human physiology": "This not only enhances the scientific rigor and precision of drug development but also reduces R&D costs, allowing innovative therapies to reach the general public at more affordable prices."